Liberty Drug and Surgical, Chatham, NJ
Is Liberty Drug and Surgical registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Liberty Drug and Surgical hold a New Jersey pharmacy license?
State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks.
Has Liberty Drug and Surgical had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Feb 25, 2019) and 1 FMD-145 letter (Feb 25, 2019) for Liberty Drug and Surgical. State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Liberty Drug and Surgical
- Location
- Chatham, NJ
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 0
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Feb 25, 2019
- FDA Data Dashboard inspections
- 3 inspections: 1 OAI, 1 VAI, 1 NAI; 1 published Form 483
- Form 483 text on this page
- 1 Form 483, 13 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Liberty Drug and Surgical, a 503A facility, with 2 dated actions.
| Document | |||
|---|---|---|---|
| Feb 25, 2019 | Warning letter close-out | Warning Letter Close Out Issued 02/25/2019 | Not linked by FDA |
| Feb 25, 2019 | FMD-145 letter | FMD-145 Letter Issued 02/25/2019 | FDA copy (archived) |
An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Liberty Drug & Surgical, Chatham, NJ (FEI number 3002127548), matched to this page by exact name, city and state. It lists 3 inspections: 1 OAI, 1 VAI, 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| May 25, 2017 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3002127548 | 1017815 |
| May 22, 2015 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3002127548 | 927328 |
| May 17, 2010 | No Action Indicated (NAI) | Drug Quality Assurance (Drugs) | 3002127548 | 664978 |
Form 483s FDA has published for this site
- Jul 17, 2015: Form 483 to Liberty Drug & Surgical, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 13 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Mar 30, 2015 to May 22, 2015: 13 observations
- Firm on the cover
- Liberty Drug & Surgical, RESS 195 Main St, Chatham, NJ 07928-2405
- FEI number
- 3002127548
- Establishment type on the cover
- Producer of Sterile Drugs
- FDA district office on the cover
- 10 Waterview Blvd., 3rd Floor Parsippany, NJ 07054
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
The flow of components, drug product containers,. closures, in-process materials, and drug products though the building is not designed to prevent contamination.
Specifically,
a. The raw materials such as JV bags and containers containing the non-sterile finished drug products are labeled, sprayed with <Redacted b4> and wiped with non-sterile wipe in the uncontrolled Pharmacy area. The products are brought into the ISO 7 Anteroom and placed on the sink during personnel gowning. The transfer of products from the ISO 7 Anteroom into the ISO 6 clean room is performed without additional sanitization ofthe containers. b. The ports oflV bags are wiped with a non-sterile <Redacted b4> swabs in the ISO 5 laminar flow hood prior to being injected with a drug product.
Observation 2
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established,
Specifically, on 3/30/15, during the preparation of spraying IV bags of <Redac ted b4> with <Redacted b4>
Observation 3
Buildings used in the manufacture, processing, packing, or holding of a drug product do not have the suitable size, construction, and location to facilitate cleaning, maintenance, and proper operations.
Specifically, a. T he ISO 7 Anteroom is approximately <Redacted b4> inches in width and has a sliding door into the ISO 6 c lea n room. b. The ISO 7 Anteroom contains a sink whose water source is <Redacted b4>
Observation 4
Aseptic processing areas are deficient regarding systems for maintaining any equ ipment used to control the aseptic conditions.
Specifically, smoke studies are not performed under dynamic conditions in the ISO 6 clean room or within the ISO 5 laminar flow cabinet.
Observation 5
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically, a. Environmental monitoring which inc ludes viable air, non-viable air, and surface contact plates are not performed on a routine basis. The monitoring ofthe ISO 5 laminar flow hoods, TSO 6 clean room, and ISO 7 Anteroom is performed by an outside contract testing laboratory only~ b. Viable air and non-viable air environmental monitoring is not conducted within the ISO 5 laminar flow hood. c. Personnel monitoring, which is performed on the fingertips, is not conducted on a routine basis or each day. Procedure 03-08.0 I , Gloved Fingertip Sampling states this testing is to be comp leted at least~The finger tip has been ed in (b)(4 )
Observation 6
Clothing of personnel engaged in the manufacturing, processing, packing, and holding of drug products is not a ppropriate for the duties they perform.
a. The gowning for the sterile operations in the ISO 6 clean room consists of a non-sterile disposable laboratory coat,
a. The gowning for the sterile operations in the ISO 6 clean room consists ofa non-sterile disposable laboratory coat,
AMENDMENT1
shoe covers, a hair cover and a surgical mask.
b. On 03/30/1 5, the Phannaist within the ISO 6 clean room was observed donning sterile gloves in a manner that could compromise the sterility of the gloves. In addition, during the gowning process, the non-sterile disposable laboratory coat was observed touching the walls of the ISO 7, Anteroom.
Observation 7
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Specifically, the lint free wipes used within the ISO 6 clean room are not sterile and are stored on the supply cart outside its original container.
Observation 8
The written stability program for drug products does not include reliable, meaningful, and specific test methods .
Specifically, the establishment of beyond use date of60 days for Doxycycline I 00 mg/ml and 132 days for 17- Hydroxyprogesterone 250 mg/ml did not include test ing the product for endotoxins and sterility. Potency was the only test used to support the beyond use date.
Observation 9
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include validation of the sterilization process.
Specifically, a. <Redacted b4> in the production of Doxycycline 100 mg/ml Injection. In addition, <Redacted b4> in the production of Doxycycline 100 mg/mllnjection is <Redactedb4> and there are no studies is suitable for~finished product. b. <Redactedb4> used to sterilize product vials for Doxycycline 100 mg/ml and rubber stoppers is not qualified or routinely evaluated to ensure that it is performing as required. c. Media ti lls are not routinely perfonned. Procedure 03-07.0 1, Personnel Aseptic Media Fill Verification requires
media fill be performed at least <Redacted b4> Media fills were last performed in January of 2014.
Observation 10
Each lot ofa component, drug product container, and closure that is liable to microbiological contamination that is objectionable in view ofits intended use is not subjected to microbiological tests before use.
Specifically, non-sterile raw materials including Active Pharmaceutical Ingredients are used in the production ofsterile injectable drug products. The materials are received with a Certificate of Analysis that does not assure it is suitable for the manufacture of sterile products and does not contain results from microbiological testing performed by the vendor. Not all Active Pharmaceutical Ingredients are tested upon receipt.
Observation 11
Test procedures relative to appropriate laboratory testing for sterility and pyrogens are not followed.
Specifically, a. Method suitability as described within the compendial method has not been performed for sterility testing of Doxycycline 100 mglml and 17-Hydroxyprogesterone 250 mg/ml. b. Morphine 50 mg/ml Injection and Methadone 10 mg/ml injection are made in anticipation of orders for office supply and patient-specific prescriptions. These are not tested for endotoxin sterility, or potency.
Observation 12
Written production and process control procedures are not followed in the execution of production and process control functions and documented at the time of performance.
Specifically, written production and process control procedures are not followed, do not include details pertinent to routine operations or include details that are accurate. a. P rocedures do not include information that is accurate . For example, Procedure 03-06.0I , Surface Sampling P rocedure, states there are three classifications, ISO 5, ISO 7 and ISO 7/ 8. T he < Redacted b4> certific ation of the clean room states the three classifications are ISO 5, ISO 6 , an d ISO 7. b. Written procedures are not inclusive ofall the details required to carry out o perations . Procedure 02-04 .0 I , Sterile Compounding Area Cleaning and Disinfecting does not provide instruction on the cleaning and disin fecting agents to be used and when they ar e to be us ed . Curren tly <R ed act ed b4> is used <Redacted b4> and <Redacted b4> is used <Redacted b4>
AMENDMENT1
c. Procedures are not followed. ...
Observation 13
Procedures describing the handling of written and oral complaints related to drug products are not written or followed.
Specifically, there is no procedure for the receiving and handling ofcomplaints.
05/04120 15(Mon), 05/07/20 15(Thu), 05/22/20 15(Fri)
State board of pharmacy records
State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.